Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent/Progressive Glioblastoma
NCT02852655Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2016
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in glioblastoma (GBM) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Tumor Infiltrating T Lymphocyte Density at 2 weeks, Cell Cycle and Cancer Proliferation Genetic Signature at 2 weeks and 1 more. Started Sep 2016; status: active, not recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02852655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852655.